Absci Corporation (ABSI)

NMS – Real Time Price. Currency in USD

5.36

-0.42 (-7.35%)

At close: May 12, 2026, 4:00 PM EDT

5.44

+0.09 (1.61%)

Pre-market: May 13, 2026, 4:59 AM EDT

08.05.2026

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

08.05.2026

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.

07.05.2026

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended March 31, 2026.

05.05.2026

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

23.04.2026

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026.

21.04.2026

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

08.04.2026

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

05.05.2026

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08.04.2026

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

24.03.2026

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data

Absci Corporation (ABSI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Absci Corporation (ABSI)

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Videos

No Data

Press releases

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Videos

No Data

Press releases

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Search stocks

Absci Corporation (ABSI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Absci Corporation (ABSI)

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Videos

No Data

Press releases

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Videos

No Data

Press releases

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results